| Title |
Randomized Trial of SPI-2012 Versus Pegfilgrastim in the Management of Chemotherapy Induced Neutropenia in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) (ADVANCE) |
| Description |
The purpose of this study is to investigate an experimental drug called SPI-2012 and compare it to pegfilgrastim while the patient receives chemotherapy with docetaxel and cyclophosphamide (also called TC chemotherapy) for early stage breast cancer. SPI-2012 increases the number of white blood cells in the body and is not yet approved by the U.S. Food and Drug Administration (FDA). This study also aims to determine whether Pegfilgrastim, also known as Neulasta® is an approved drug that increases the number of white blood cells in the body. Additional information can be found on ClinicalTrials.gov |
| NCT Number |
02643420 |
| Start Date |
11/01/2015 |
| Status |
Active; closed to enrollment |
| Principal Name |
Kerry Pulver, MD |
| Contact Name |
Tina Schied, RN, CCRC |
| Phone |
(208)367-3481 |
